Carborundum Universal will hold a meeting of the Board of Directors of the Company on 3 May 2024.

Hindustan Construction Company has appointed Girish Gangal as Chief Financial Officer with effect from 18 April 2024. He replaces Rahul Rao who resigned on 18 April 2024.

Tata Investment Corporation has postponed the meeting of the Board of Directors which was scheduled to be held on . The meeting will now be held on 24 April 2024.

ITC announced that its wholly owned subsidiary - ITC Infotech India has entered into a share purchase agreement for acquisition of 100% of the share capital of Blazeclan Technologies. The total consideration is up to Rs 485 crore including contingent consideration which is subject to achievement of prescribed targets.

Blazeclan is a born-in-the-cloud consulting company providing cloud services on AWS, Azure and GCP, and has been recognized as a Niche Player in the 2023 Gartner® Magic Quadrant for Public Cloud IT Transformation Services.

This acquisition is expected to augment ITC Infotech's capabilities to service its customers in a multi-cloud and hybrid cloud environment with focus on the Partner eco-system to accelerate future growth.

The acquisition is expected to strengthen ITC Infotech's commitment to helping clients navigate their digital transformation journey and deliver business outcomes built on the foundation of strong Cloud capabilities.

Trent will hold a meeting of the Board of Directors of the Company on 29 April 2024.

Oriental Hotels announced that the Board of Directors of the Company at its meeting held on 18 April 2024, inter alia, have recommended the final dividend of Rs 0.5 per equity Share (i.e. 50%) , subject to the approval of the shareholders.

Shree Cement has received reaffirmation in credit rating for commercial paper of Rs 500 crore at CARE A1+.

Talbros Automotive Components announced order win from a large European OEM for a multi-year contract valued at approximately Rs. 1,000 crore. These orders are to be executed over a period of next 8 years commencing from Q4FY25. The Order win is by TACL's Joint Venture Company, Marelli Talbros Chassis Systems (MTCS).

This order is centered on the supply of Suspension Arms tailored for both conventional Internal Combustion Engine (ICE) vehicles and new age Electric Vehicle (EV) platforms for EMEA and NAFTA regions. The production for the same would be done from the Pune plant of MTCS for which a capex investment of ~Rs. 65 crore is envisaged in FY25. The investments would be done through internal accruals and debt.

This order adds a new customer for TACL group in Europe, which is a highly specialized market for automotive components. This will further improve the market share in Europe and open new avenues of growth with existing and new OEMs in the region.

Last year, the Company received orders to the tune of ~“Rs 980 crore across varied products segments in standalone and JV company. Amongst these, orders worth ~Rs. 475 crores were for supply for EV segment. Furthermore, orders worth ~ Rs. 415 crore were related to exports. Coupled with order wins in FY24, TACL anticipates continued momentum in business and profitability

Jubilant Pharmova announced that the company's subsidiary, Jubilant Cadista Pharmaceuticals Inc., USA has decided to close the manufacturing operations of its solid dosage formulation facility at Salisbury, Maryland, USA. The expected date of cessation of manufacturing operation and first separations at the said facility will be on 17 June 2024. Jubilant Cadista will continue the sales and marketing operations for US market. The said facility manufactures tablets and capsules for the US market and has the capacity to serve 1.5 billion doses.

Jubilant Cadista is a subsidiary of Jubilant Pharma Holdings Inc., USA, which is held by Jubilant Pharma, Singapore, a wholly owned subsidiary of the Company.

Over the last few years the US Generics market has been witnessing significant pricing pressure leading to significant losses at Jubilant Cadista since FY2022 onwards.

In order to move the US generics business to profitability, it has been decided to change the operating model from in-house manufacturing to outsourced manufacturing by selected USFDA approved CMOs for the US market.

Further, following the status change of Jubilant Generics Limited's (‘JGL') Roorkee facility by USFDA to VAI, the company expects the exports from the Roorkee facility to the US market to increase in a meaningful and gradual manner. As of now the facility, was exporting only one product, Risperidone to the US market. JGL is a subsidiary of Jubilant Pharma Ltd, a wholly owned subsidiary of the company.

These actions are expected to improve the gross margins of the Generics business by reducing manufacturing, quality management and overhead costs, which will drive the generics business towards profitability. Lastly, the Generics business has plans to scale up revenues in the US market through launch of new products.

Jubilant Cadista shall continue to explore various options to utilize or sell the said facility's Land, Building and Plant & Machinery in the due course.

VST Industries will hold a meeting of the Board of Directors of the Company on 26 April 2024.